Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline-rich protein 20E is a member of a cluster of five genes at chromosome 13q21.1 encoding proline-rich proteins, with several predicted motifs similar to those found in dopamine D4 receptors but lacking a defined or characterized biological function[2]. As of now, this protein is not recognized as a therapeutic target, and there are no data describing its role in disease, druggability, or as a functional biomarker[2]. Studies of proline-rich proteins in general suggest possible involvement in protein-protein interactions and cellular signaling, but these findings have not been linked specifically to PRR20E[4][5]. PRR20E is a little-studied gene with no experimental evidence tying it to known signaling pathways, pathological processes, or molecular functions beyond its high proline content and clustered genomic organization[2]. Proline-rich proteins as a group may contribute to protein-protein interactions, cytoskeletal regulation, and other cellular processes, but there is no direct evidence for these functions in PRR20E[4][5]. No literature or databases currently designate PRR20E as a disease gene or therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline-rich protein 20E (PRR20E).